Medicaid’s Institution for Mental Diseases (IMD) rule bars federal funding for psychiatric facilities with more than 16 beds, but findings indicate that state waivers allowing treatment of serious mental illness in IMDs do not increase overall psychiatric hospitalizations.
A phase 3 trial shows lumateperone added to antidepressant therapy delivers greater symptom improvement and maintains a favorable safety profile in adults with MDD.